<s>
Gadoteric	B-Architecture
acid	I-Architecture
,	O
sold	O
under	O
the	O
brand	O
name	O
Dotarem	B-Architecture
among	O
others	O
,	O
is	O
a	O
macrocycle-structured	O
gadolinium-based	O
MRI	B-Algorithm
contrast	O
agent	O
(	O
GBCA	O
)	O
.	O
</s>
<s>
It	O
consists	O
of	O
the	O
organic	O
acid	O
DOTA	O
as	O
a	O
chelating	O
agent	O
,	O
and	O
gadolinium	O
(	O
Gd3+	O
)	O
,	O
and	O
is	O
used	O
in	O
form	O
of	O
the	O
meglumine	O
salt	O
(	O
gadoterate	B-Architecture
meglumine	I-Architecture
)	O
.	O
</s>
<s>
The	O
paramagnetic	O
property	O
of	O
gadoteric	B-Architecture
acid	I-Architecture
reduces	O
the	O
T1	B-Algorithm
relaxation	I-Algorithm
time	O
(	O
and	O
to	O
some	O
extent	O
the	O
T2	O
and	O
T2*	O
relaxation	B-Algorithm
times	O
)	O
in	O
MRI	B-Algorithm
,	O
which	O
is	O
the	O
source	O
of	O
its	O
clinical	O
utility	O
.	O
</s>
<s>
Because	O
it	O
has	O
magnetic	O
properties	O
,	O
gadoteric	B-Architecture
acid	I-Architecture
develops	O
a	O
magnetic	O
moment	O
when	O
put	O
under	O
a	O
magnetic	O
field	O
,	O
which	O
increases	O
the	O
signal	O
intensity	O
(	O
brightness	O
)	O
of	O
tissues	O
during	O
MRI	B-Algorithm
imaging	O
.	O
</s>
<s>
Gadoteric	B-Architecture
acid	I-Architecture
is	O
used	O
for	O
MRI	B-Algorithm
imaging	O
of	O
the	O
brain	O
,	O
spine	O
,	O
and	O
associated	O
tissues	O
for	O
adult	O
and	O
pediatric	O
(	O
2	O
years	O
of	O
age	O
or	O
older	O
)	O
patients	O
.	O
</s>
<s>
The	O
meglumine	O
salt	O
it	O
takes	O
the	O
form	O
of	O
crosses	O
the	O
blood	O
brain	O
barrier	O
of	O
tissue	O
with	O
abnormal	O
vasculature	O
,	O
highlighting	O
the	O
affected	O
area	O
with	O
MRI	B-Algorithm
.	O
</s>
<s>
Gadoterate	B-Architecture
does	O
not	O
cross	O
the	O
intact	O
blood-brain	O
barrier	O
,	O
so	O
it	O
does	O
not	O
affect	O
or	O
enhance	O
normal	O
brain	O
tissue	O
in	O
imaging	O
.	O
</s>
<s>
Dotarem	B-Architecture
is	O
administered	O
through	O
an	O
intravenous	O
bolus	O
injection	O
,	O
either	O
manually	O
or	O
through	O
a	O
power	O
injection	O
.	O
</s>
<s>
A	O
2020	O
study	O
found	O
Clariscan	B-Architecture
was	O
retained	O
more	O
in	O
the	O
cerebrum	O
,	O
cerebellum	O
,	O
kidney	O
and	O
liver	O
of	O
rats	O
than	O
those	O
injected	O
with	O
Dotarem	B-Architecture
.	O
</s>
<s>
The	O
drug	O
,	O
under	O
the	O
brand	O
name	O
Dotarem	B-Architecture
,	O
was	O
brought	O
to	O
market	O
by	O
Guerbet	O
.	O
</s>
<s>
As	O
of	O
2013	O
,	O
gadoteric	B-Architecture
acid	I-Architecture
was	O
approved	O
in	O
around	O
70	O
countries	O
.	O
</s>
<s>
Dotarem	B-Architecture
is	O
the	O
seventh	O
FDA-approved	O
GBCA	O
for	O
use	O
in	O
central	O
nervous	O
system	O
MRI	B-Algorithm
.	O
</s>
<s>
In	O
2019	O
,	O
GE	O
Healthcare	O
launched	O
gadoteric	B-Architecture
acid	I-Architecture
medication	O
(	O
as	O
gadoterate	B-Architecture
meglumine	I-Architecture
)	O
under	O
the	O
brand	O
name	O
Clariscan	B-Architecture
.	O
</s>
